Last update Aug. 28, 2020
It is an angiotensin II receptor antagonist with actions similar to those of losartan.
It is indicated in the treatment of hypertension.
Oral administration once a day.
At latest update, relevant published data on excretion into breast milk were not found.
Because of a high protein-binding capacity, a significant excretion into breast milk is unlikely.
However, it is one among the Sartan drugs (ARA-II type) with the longest half-life and highest oral bioavailability (Tamargo 2006). The latter properties make it less convenient for use while breastfeeding.
Reportedly, a newborn infant appeared with transient renal failure (kidney malfunction) whose mother had taken Telmisartan during pregnancy (Pietrement 2003).
Until more data on this medication is available safer alternative drugs are preferred (Malachias 2016, Rowe 2013) especially in premature babies or during the neonatal period.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM